share_log

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

我们认为股东可能想考虑对Arrowhead Pharmicals, Inc.进行审查。”s(纳斯达克股票代码:ARWR)首席执行官薪酬待遇
Simply Wall St ·  03/08 06:33

Key Insights

关键见解

  • Arrowhead Pharmaceuticals to hold its Annual General Meeting on 14th of March
  • Salary of US$902.5k is part of CEO Chris Anzalone's total remuneration
  • The total compensation is 51% higher than the average for the industry
  • Arrowhead Pharmaceuticals' EPS declined by 24% over the past three years while total shareholder loss over the past three years was 54%
  • Arrowhead Pharmicals将于3月14日举行年度股东大会
  • 902.5万美元的薪水是首席执行官克里斯·安扎隆总薪酬的一部分
  • 总薪酬比该行业的平均水平高出51%
  • 在过去三年中,Arrowhead Pharmaceuticals的每股收益下降了24%,而过去三年的股东总亏损为54%

Shareholders will probably not be too impressed with the underwhelming results at Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) recently. Shareholders can take the chance to hold the board and management accountable for the unsatisfactory performance at the next AGM on 14th of March. This will be also be a chance where they can challenge the board on company direction and vote on resolutions such as executive remuneration. The data we present below explains why we think CEO compensation is not consistent with recent performance.

Arrowhead Pharmicals, Inc.(纳斯达克股票代码:ARWR)最近表现不佳的业绩可能不会给股东留下太深刻的印象。股东们可以借此机会在3月14日的下一次股东周年大会上追究董事会和管理层对表现不佳的责任。这也将是他们就公司方向向董事会提出质疑并对高管薪酬等决议进行表决的机会。我们在下面提供的数据解释了为什么我们认为首席执行官的薪酬与最近的表现不一致。

Comparing Arrowhead Pharmaceuticals, Inc.'s CEO Compensation With The Industry

比较 Arrowhead Pharmicals, Inc.”s 首席执行官向业界提供的薪酬

According to our data, Arrowhead Pharmaceuticals, Inc. has a market capitalization of US$4.1b, and paid its CEO total annual compensation worth US$9.9m over the year to September 2023. That's a notable decrease of 18% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$903k.

根据我们的数据,Arrowhead Pharmicals, Inc.的市值为41亿美元,在截至2023年9月的一年中,向其首席执行官支付的年薪总额为990万美元。这比去年显著下降了18%。我们认为总薪酬更为重要,但我们的数据显示,首席执行官的薪水较低,为903万美元。

On comparing similar companies from the American Biotechs industry with market caps ranging from US$2.0b to US$6.4b, we found that the median CEO total compensation was US$6.6m. Hence, we can conclude that Chris Anzalone is remunerated higher than the industry median. Moreover, Chris Anzalone also holds US$123m worth of Arrowhead Pharmaceuticals stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

在比较美国生物技术行业中市值从20亿美元到64亿美元不等的类似公司时,我们发现首席执行官的总薪酬中位数为660万美元。因此,我们可以得出结论,克里斯·安扎隆的薪酬高于行业中位数。此外,克里斯·安扎隆还直接以自己的名义持有价值1.23亿美元的Arrowhead Pharmicals股票,这向我们表明他们在该公司拥有大量个人股份。

Component 2023 2022 Proportion (2023)
Salary US$903k US$863k 9%
Other US$9.0m US$11m 91%
Total Compensation US$9.9m US$12m 100%
组件 2023 2022 比例 (2023)
工资 903 万美元 863 万美元 9%
其他 9.0 万美元 1100 万美元 91%
总薪酬 9.9 万美元 1200 万美元 100%

Talking in terms of the industry, salary represented approximately 23% of total compensation out of all the companies we analyzed, while other remuneration made up 77% of the pie. Arrowhead Pharmaceuticals pays a modest slice of remuneration through salary, as compared to the broader industry. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.

就行业而言,在我们分析的所有公司中,工资约占总薪酬的23%,而其他薪酬占总薪酬的77%。与整个行业相比,Arrowhead Pharmicals通过工资支付的薪酬微不足道。如果非工资薪酬在总薪酬中占主导地位,则表明高管的薪水与公司业绩息息相关。

ceo-compensation
NasdaqGS:ARWR CEO Compensation March 8th 2024
纳斯达克GS:ARWR 首席执行官薪酬 2024 年 3 月 8 日

A Look at Arrowhead Pharmaceuticals, Inc.'s Growth Numbers

看看 Arrowhead Pharmicals, Inc.”s 增长数字

Over the last three years, Arrowhead Pharmaceuticals, Inc. has shrunk its earnings per share by 24% per year. Its revenue is down 35% over the previous year.

在过去的三年中,Arrowhead Pharmicals, Inc.的每股收益每年缩水24%。其收入比上年下降了35%。

Overall this is not a very positive result for shareholders. And the impression is worse when you consider revenue is down year-on-year. It's hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

总体而言,这对股东来说并不是一个非常积极的结果。当你考虑到收入同比下降时,印象会更糟。很难说该公司正在全力以赴,因此股东可能不愿接受高额的首席执行官薪酬。历史表现有时可以很好地衡量接下来会发生什么,但是如果你想展望公司的未来,你可能会对这种免费的分析师预测可视化感兴趣。

Has Arrowhead Pharmaceuticals, Inc. Been A Good Investment?

Arrowhead Pharmicals, Inc. 是一项不错的投资吗?

Few Arrowhead Pharmaceuticals, Inc. shareholders would feel satisfied with the return of -54% over three years. So shareholders would probably want the company to be less generous with CEO compensation.

很少有Arrowhead Pharmicals, Inc.的股东会对三年内-54%的回报率感到满意。因此,股东们可能希望公司在首席执行官薪酬方面不那么慷慨。

In Summary...

总而言之...

Given that shareholders haven't seen any positive returns on their investment, not to mention the lack of earnings growth, this may suggest that few of them would be willing to award the CEO with a pay rise. At the upcoming AGM, management will get a chance to explain how they plan to get the business back on track and address the concerns from investors.

鉴于股东没有看到任何正的投资回报,更不用说收益增长不足了,这可能表明他们中很少有人愿意向首席执行官加薪。在即将举行的股东周年大会上,管理层将有机会解释他们计划如何使业务重回正轨并解决投资者的担忧。

CEO compensation can have a massive impact on performance, but it's just one element. That's why we did some digging and identified 2 warning signs for Arrowhead Pharmaceuticals that you should be aware of before investing.

首席执行官薪酬可以对绩效产生巨大影响,但这只是一个因素。这就是为什么我们进行了一些挖掘并确定了Arrowhead Pharmicals的两个警告信号,在投资之前你应该注意这些信号。

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

可以说,业务质量比首席执行官的薪酬水平重要得多。因此,请查看这份免费清单,列出了股本回报率高、负债率低的有趣公司。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发